The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.